Department of Gastrointestinal Surgery, Beijing Cancer Hospital and Institute, Peking University School of Oncology, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Beijing 100142, China;
Chin J Cancer Res. 2013 Oct;25(5):600-2. doi: 10.3978/j.issn.1000-9604.2013.10.14.
Gastrointestinal stromal tumors (GISTs) occur most frequently in the stomach. Diagnosis of gastric GIST is not always clear before surgery. Flexible endoscopy may suggest the nature of the lesion (a bulky tumor with preserved mucosa); however, biopsy is rarely diagnostic. Therefore, diagnostic medication with safe drugs may provide a feasible way under such conditions after an informed consent is obtained. Based on the excellent efficacy of imatinib mesylate (IM) in the treatment of GIST, we successfully applied it in the diagnostic medication of two patients with clinically suspected gastric stromal tumors. In conclusion, the diagnostic medication with IM can be an alternative option for patients with suspected GIST that can not be confirmed pathologically.
胃肠道间质瘤（GISTs）最常发生于胃部。在手术前，胃部 GIST 的诊断并不总是明确的。软性内视镜检查可能提示病变的性质（有肿块但保留黏膜的肿瘤）；然而，活检很少具有诊断意义。因此，在获得知情同意后，在这种情况下，使用安全药物进行诊断性药物治疗可能是一种可行的方法。基于甲磺酸伊马替尼（IM）在 GIST 治疗中的卓越疗效，我们成功地将其应用于两例临床疑似胃间质瘤患者的诊断性药物治疗中。总之，对于那些无法通过病理证实的疑似 GIST 患者，IM 的诊断性药物治疗是一种可供选择的方法。
